The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies

The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL

(2015) K Balakrishnan et al.   LEUKEMIA

IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells

(2014) S. Dong et al.   BLOOD

PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models

(2013) David G. Winkler et al.   CHEMISTRY & BIOLOGY

The Paradox of Akt-mTOR Interactions

(2013) Lakshmipathi Vadlakonda et al.   Frontiers in Oncology

Targeting Nonclassical Oncogenes for Therapy in T-ALL

(2012) Prem S. Subramaniam et al.   CANCER CELL

PI3Kδ and PI3Kγ as Targets for Autoimmune and Inflammatory Diseases

(2012) Timothy D. Cushing et al.   JOURNAL OF MEDICINAL CHEMISTRY

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

(2011) J. Hoellenriegel et al.   BLOOD

PI3K  Plays a Critical Role in Neutrophil Activation by Immune Complexes

(2011) S. Kulkarni et al.   Science Signaling

CAL-101, a p110  selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

(2010) B. J. Lannutti et al.   BLOOD

Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function

(2010) Wai-Ping Fung-Leung   CELLULAR SIGNALLING

PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation

(2008) Cristiana Guiducci et al.   JOURNAL OF EXPERIMENTAL MEDICINE